BCRX Q2 2017 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q2 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-35.3% YoY

Gross Profit

$3M99.3% margin

Operating Income

-$16M-500.7% margin

Net Income

-$17M-544.9% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

-67.2%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$114M

Total Liabilities

$89M

Stockholders' Equity

$24M

Cash & Equivalents

$40M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$5M	-35.3%
Gross Profit	$3M	$5M	-35.4%
Operating Income	-$16M	-$12M	-27.9%
Net Income	-$17M	-$16M	-3.7%